Literature DB >> 33587281

Regional prefrontal cortical atrophy predicts specific cognitive-behavioral symptoms in ALS-FTD.

Elena Ratti1,2,3,4,5,6, Kimiko Domoto-Reilly7,8,9,10, Christina Caso7,10, Alyssa Murphy11,12, Michael Brickhouse7, Daisy Hochberg7,13, Nikos Makris14, Merit E Cudkowicz11,12, Bradford C Dickerson7,8,9.   

Abstract

Amyotrophic Lateral Sclerosis-Frontotemporal Dementia (ALS-FTD) may present typical behavioral variant FTD symptoms. This study aims to determine whether profile and severity of cognitive-behavioral symptoms in ALS/ALS-FTD are predicted by regional cortical atrophy. The hypothesis is that executive dysfunction can be predicted by dorsolateral prefrontal cortical (dlPFC) atrophy, apathy by dorsomedial PFC (dmPFC) and anterior cingulate cortical (ACC) atrophy, disinhibition by orbitofrontal cortical (OFC) atrophy. 3.0 Tesla MRI scans were acquired from 22 people with ALS or ALS-FTD. Quantitative cortical thickness analysis was performed with FreeSurfer. A priori-defined regions of interest (ROI) were used to measure cortical thickness in each participant and calculate magnitude of atrophy in comparison to 115 healthy controls. Spearman correlations were used to evaluate associations between frontal ROI cortical thickness and cognitive-behavioral symptoms, measured by Neuropsychiatric Inventory Questionnaire (NPI-Q) and Clinical Dementia Rating (CDR) scale. ALS-FTD participants exhibited variable degrees of apathy (NPI-Q/apathy: 1.6 ± 1.2), disinhibition (NPI-Q/disinhibition: 1.2 ± 1.2), executive dysfunction (CDR/judgment-problem solving: 1.7 ± 0.8). Within the ALS-FTD group, executive dysfunction correlated with dlPFC atrophy (ρ:-0.65;p < 0.05); similar trends were seen for apathy with ACC (ρ:-0.53;p < 0.10) and dmPFC (ρ:-0.47;p < 0.10) atrophy, for disinhibition with OFC atrophy (ρ:-0.51;p < 0.10). Compared to people with ALS, those with ALS-FTD showed more diffuse atrophy involving precentral gyrus, prefrontal, temporal regions. Profile and severity of cognitive-behavioral symptoms in ALS-FTD are predicted by regional prefrontal atrophy. These findings are consistent with established brain-behavior models and support the role of quantitative MRI in diagnosis, management, counseling, monitoring and prognostication for a neurodegenerative disorder with diverse phenotypes.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Amyotrophic lateral sclerosis (4); Cerebral cortex (2); Frontal lobe (5); Frontotemporal dementia (3); Magnetic resonance imaging (1)

Mesh:

Year:  2021        PMID: 33587281      PMCID: PMC8862734          DOI: 10.1007/s11682-021-00456-1

Source DB:  PubMed          Journal:  Brain Imaging Behav        ISSN: 1931-7557            Impact factor:   3.224


  87 in total

1.  Cognitive functions and white matter tract damage in amyotrophic lateral sclerosis: a diffusion tensor tractography study.

Authors:  L Sarro; F Agosta; E Canu; N Riva; A Prelle; M Copetti; G Riccitelli; G Comi; M Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2011-10-20       Impact factor: 3.825

2.  Semantic deficits in amyotrophic lateral sclerosis.

Authors:  Felicity V C Leslie; Sharpley Hsieh; Jashelle Caga; Sharon A Savage; Eneida Mioshi; Michael Hornberger; Matthew C Kiernan; John R Hodges; James R Burrell
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-12-27       Impact factor: 4.092

3.  Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study.

Authors:  Taha Omer; Eoin Finegan; Siobhan Hutchinson; Mark Doherty; Alice Vajda; Russell L McLaughlin; Niall Pender; Orla Hardiman; Peter Bede
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-05-31       Impact factor: 4.092

Review 4.  The cognitive profile of ALS: a systematic review and meta-analysis update.

Authors:  Emma Beeldman; Joost Raaphorst; Michelle Klein Twennaar; Marianne de Visser; Ben A Schmand; Rob J de Haan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-08-17       Impact factor: 10.154

5.  The UCSF screening exam effectively screens cognitive and behavioral impairment in patients with ALS.

Authors:  Jennifer Murphy; Fizaa Ahmed; Catherine Lomen-Hoerth
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-10-10       Impact factor: 4.092

Review 6.  Is there a dysexecutive syndrome?

Authors:  Donald T Stuss; Michael P Alexander
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-05-29       Impact factor: 6.237

7.  Measurement of Social Cognition in Amyotrophic Lateral Sclerosis: A Population Based Study.

Authors:  Tom Burke; Marta Pinto-Grau; Katie Lonergan; Marwa Elamin; Peter Bede; Emmet Costello; Orla Hardiman; Niall Pender
Journal:  PLoS One       Date:  2016-08-24       Impact factor: 3.240

8.  Apathy Is Correlated with Widespread Diffusion Tensor Imaging (DTI) Impairment in Amyotrophic Lateral Sclerosis.

Authors:  Cinzia Femiano; Francesca Trojsi; Giuseppina Caiazzo; Mattia Siciliano; Carla Passaniti; Antonio Russo; Alvino Bisecco; Mario Cirillo; Maria Rosaria Monsurrò; Fabrizio Esposito; Gioacchino Tedeschi; Gabriella Santangelo
Journal:  Behav Neurol       Date:  2018-10-22       Impact factor: 3.342

9.  Screening for cognition and behaviour changes in ALS.

Authors:  Sharon Abrahams; Judith Newton; Elaine Niven; Jennifer Foley; Thomas H Bak
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2013-06-19       Impact factor: 4.092

10.  Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum.

Authors:  Patricia Lillo; Eneida Mioshi; James R Burrell; Matthew C Kiernan; John R Hodges; Michael Hornberger
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

View more
  1 in total

Review 1.  Feature selection from magnetic resonance imaging data in ALS: a systematic review.

Authors:  Thomas D Kocar; Hans-Peter Müller; Albert C Ludolph; Jan Kassubek
Journal:  Ther Adv Chronic Dis       Date:  2021-10-13       Impact factor: 5.091

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.